[EN] NOVEL COMPOUNDS FOR MODULATION OF ROR-GAMMA ACTIVITY<br/>[FR] NOUVEAUX COMPOSÉS POUR LA MODULATION DE L'ACTIVITÉ ROR-GAMMA
申请人:BIOGEN IDEC INC
公开号:WO2014028669A1
公开(公告)日:2014-02-20
The present invention relates to aryl sulfones and related compounds that are modulators of ROR-gamma receptors. The invention also provides pharmaceutical compositions comprising these modulators, and methods of modulating ROR-gamma receptors using them. Also provided are methods of using aryl sulfones and related compounds as modulators of ROR-gamma to treat ROR-gamma mediated diseases.
Scavenger assisted combinatorial process for preparing libraries of amides, carbamates and sulfonamides
申请人:ELI LILLY AND COMPANY
公开号:EP0825164A2
公开(公告)日:1998-02-25
This invention relates to a novel solution phase process for the preparation of amide, carbamate, and sulfonamide combinatorial libraries. These libraries have utility for drug discovery and are used to form wellplate components of novel assay kits.
[EN] SUBSTITUTED HETEROCYCLIC AMINE DERIVATIVES AS MULTIKINASE INHIBITORS FOR THE TREATMENT OF CANCER<br/>[FR] DÉRIVÉS D'AMINE HÉTÉROCYCLIQUES SUBSTITUÉS COMME INHIBITEURS DE MULTIKINASE POUR LE TRAITEMENT DU CANCER
申请人:PIRAMAL ENTPR LTD
公开号:WO2015128698A1
公开(公告)日:2015-09-03
The present invention relates to compounds of formula (I), their isotopic forms, stereoisomeric forms, tautomeric forms, pharmaceutically acceptable salts, pharmaceutically acceptable solvates, prodrugs, polymorphs or N-oxides thereof. The present invention also relates to processes for the preparation of compounds of formula (I) and pharmaceutical compositions comprising the compounds of formula (I). The compounds and their pharmaceutical compositions are multikinase inhibitors and are useful in the treatment of proliferative disorders, such as cancers.
Decarboxylative Borylation of <i>m</i>CPBA-Activated Aliphatic Acids
作者:Dian Wei、Tu-Ming Liu、Bo Zhou、Bing Han
DOI:10.1021/acs.orglett.9b04218
日期:2020.1.3
A decarboxylative borylation of aliphatic acids for the synthesis of a variety of alkylboronates has been developed by mixing m-chloroperoxybenzoic acid (mCPBA)-activated fatty acids with bis(catecholato)diboron in N,N-dimethylformamide (DMF) at room temperature. A radical chain process is involved in the reaction which initiates from the B-B bond homolysis followed by the radical transfer from the
Diaminopyrimidine derivatives as growth hormone secrectgogue receptor (GHS-R) antagonists
申请人:Kosogof Christi
公开号:US20050171131A1
公开(公告)日:2005-08-04
The present invention is related to compounds of formula (I),
or a therapeutically suitable salt or prodrug thereof, the preparation of the compounds, compositions containing the compounds and the use of the compounds in the prevention or treatment of disorders regulated by the action of ghrelin receptor, including Prader-Willi syndrome, eating disorder, weight gain, weight-loss maintainance following diet and exercise, obesity, and disorders associated with obesity such as noninsulin dependent diabetes mellitus.